Real-world dapagliflozin experience in patients with heart failure in Greece - EVOLUTION-HF

Study identifier:D1699R00046

ClinicalTrials.gov identifier:NCT05635331

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

Early treatment of heart failure: a non-interventional observational study program of patients with heart failure and initiated on dapagliflozin (EVOLUTION-HF - GREECE)

Medical condition

heart failure

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

257

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 28 Dec 2022
Estimated Primary Completion Date: 31 Mar 2025
Estimated Study Completion Date: 31 Mar 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria